New yellow fever vaccine passes early safety check in small trial
NCT ID NCT05172544
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 29 times
Summary
This early-stage trial tested a new inactivated yellow fever vaccine called HydroVax-002 YFV in 26 healthy adults aged 18 to 49. Participants received two shots of either a low or high dose of the vaccine or a placebo, given one month apart. The main goal was to check safety and side effects, while also measuring how well the vaccine triggered an immune response. Results will help decide if larger studies should move forward.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for YELLOW FEVER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Health System
Durham, North Carolina, 27705, United States
Conditions
Explore the condition pages connected to this study.